Introduction
Cardiac hypertrophy is characterized by an increase in the cell surface area of individual myocytes, enhanced sarcomeric organization, and the abnormal expression of fetal genes (1) . In addition, cardiac hypertrophy is associated with alterations in intracellular signal transduction pathways, including ways may offer an attractive therapeutic target for the suppression of cardiac hypertrophy and congestive heart failure.
PKC has been identified as an important component of the signal transduction pathway used by cells to respond to a variety of extracellular stimuli. PKC comprises a family of serine-threonine protein kinases that can be classified into three major categories (7) (8) (9) . The conventional PKC isoforms (α, β, γ) are characterized enzymatically by their requirement for calcium, phospholipids, and diacylglycerol or phorbolester for activation. The novel PKC isoforms (δ, ε, θ, η) lack the calcium-binding domain and do not require calcium for activation (9, 10) . The atypical PKC isoforms (aPKCs; ζ, ι/λ) also differ from other members of the PKC gene family in that they contain only one cysteine-rich zinc finger like motif in the C1 domain. Neither calcium nor diacylglycerol/phorbolester activates these PKC isoforms (11) (12) (13) .
Recent studies have suggested that PKC is critically involved in the development of cardiac hypertrophy and heart failure. Furthermore, the data also suggest that individual PKC isoforms have different effects on cell signaling pathways, variously leading to changes in cardiac contractility, hypertrophic response, and tolerance to myocardial ischemia in the heart (14) (15) (16) (17) . The goal of the present study was to examine the pattern of PKC isoform expression during the course of cardiac remodeling. Changes in the expression of PKC isoforms in cardiac hypertrophy and heart failure could reflect their primary roles or a secondary phenomenon of these diseases. To date, there have been few reports comparing the patterns of all kinds of PKC expression including aPKCs between cardiac hypertrophy and heart failure in the same model system. Several reports have suggested that Dahl salt-sensitive rats are a suitable model for the comparison between cardiac hypertrophy and congestive heart failure in this loading protocol (18) (19) (20) (21) (22) . In this study, we found different PKC isoform-specific patterns of upregulation at the cardiac hypertrophy stage and heart failure stage.
Methods

Animals
Four week-old male Dahl salt-sensitive rats were purchased from Tsukuba Research Laboratory (Eisai Co., Tokyo, Japan). These rats originated from the inbred colony kept at Brookhaven National Laboratories (Upton, New York, USA). The rats were housed three animals per cage and maintained under controlled conditions of light, temperature, and humidity. All animals had free access to tap water and normal rat chow containing 0.3% NaCl.
Two weeks after purchase, at 6 weeks of age, the rats were divided into two groups and placed on either a high-salt (8% NaCl) or a low-salt (0.3% NaCl) diet. Systolic blood pressure was measured by the tail-cuff method of Friedman and Freed at 6, 8 and 12 weeks of age (23) . Rats were killed at 11 weeks of age at the cardiac hypertrophy stage or at 16 weeks at the congestive heart failure stage (18) (19) (20) (21) (22) . The hearts were dissected out and immediately frozen in liquid nitrogen for Western blot analysis.
The animals were maintained and the experiments conducted at the Yokokama City University School of Medicine Laboratory Animal Facility. The experiments were conducted under the guidelines for animal experiments set by the Animal Experiment Committee of Yokohama City University School of Medicine.
Antibodies
The antibodies used in this study were anti-PKCα antibody, α1 (provided by Yoshiko Akita, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan), anti-PKCβII antibody (Santa Cruz Biotechnology, Santa Cruz, USA), anti-PKCδ antibody (Transduction Laboratories, Lexington, USA), anti-PKCε antibody (Gibco BRL, Gaithersburg, USA), and anti-PKCζ antibody (Santa Cruz Biotechnology).
Sodium Dodecyl Sulfate (SDS)-Polyacrylamide Gel Electrophoresis (PAGE) and Immunoblot Analysis
For analysis of PKC expression in heart tissues of Dahl saltsensitive rats, tissue blocks were crushed using a Cryo-Press Diatron (Microtec Co., Ltd., Chiba, Japan), precooled in liquid nitrogen, and the resultant powder was suspended in 10 vol (vol/wt) of SDS sample buffer, homogenized with a Polytron homogenizer (Kinematica, Luzerne, Switzerland), and sonicated. Total heart extracts, 20 µg per lane, were analyzed for the expression of PKC isoforms by SDS-PAGE (10% polyacrylamide). The separated proteins were transferred onto polyvinylidene difluoride (PVDF) membranes, which were then blocked with 5% skim milk. The membranes were 
Results
Systolic Blood Pressure in Dahl Salt-Sensitive Rats
As shown in Table 1 , systolic blood pressure differed between Dahl salt-sensitive rats fed the high-salt diet (8%) and those fed the low-salt diet (0.3%). Salt loading (8%) significantly increased systolic blood pressure. Rats fed the lowsalt diet tended to show an increase in systolic blood pressure in a time-dependent manner, but the pressure did not reach the range of hypertension during the course of the study (24) (25) (26) . Body weight was lower in rats fed the highsalt diet than in those fed the low-salt diet because rats fed the high-salt diet demonstrated appetite loss. Among the total of 12 rats fed the high-salt diet, 6 rats died and 6 rats survived to the heart failure stage. That is, half of the high-salt loading group died of congestive heart failure by 16 weeks of age (18) . This loading protocol was developed to yield rats that show cardiac hypertrophy at 11 weeks of age and congestive heart failure rats at 16 weeks of age (18) (19) (20) (21) (22) (27) (28) (29) .
Isoform-Specific PKC Expression at Two Different Stages in the Hearts of Dahl Salt-Sensitive Rats
Conventional PKCα, β, novel PKCδ, ε, η, and aPKCs ζ, ι/λ were detected in the heart by Western blot analysis (Fig. 1 ).
PKCγ appears to be expressed solely in the brain and spinal cord. PKCθ appears especially in T cells and skeletal muscle (10) . PKCη and λ were detected, but the degree of expression was too small to be evaluated, and the change in expression did not seem to be significant. Western blot analysis of individual PKC isoforms was performed as described previously. However, it should be noted that the anti-PKCζ antibody does not discriminate between PKCζ and PKCι/λ, which are structurally highly homologous to PKCζ in the COOH-terminal end of the molecule (11-13). We used anti-PKCζ antibody as the antibody to recognize both PKCζ and PKC ι/λ (aPKCs). The amount of all PKC isoforms (PKCα, β, δ, ε, and aPKCs) increased at the cardiac hypertrophy stage and congestive heart failure stage in Dahl salt-sensitive rats, but the pattern of increase differed among PKC isoforms at the heart failure stage. The high salt-diet caused increases in PKCα, β, and δ of about 1.5-to 2-fold (the high salt-diet vs. the low salt-diet at the same age) at the cardiac hypertrophy stage, and these increases were maintained at 1.4-to 2-fold at the heart failure stage. On the other hand, the high-salt diet caused increases in PKCε and aPKCs of about 1.5-fold at the cardiac hypertrophy stage, similar to PKCα, β and δ, but the increase was significantly diminished to about 1.2-fold at the congestive heart failure stage.
Fig. 1. Expression of PKC isoforms in Dahl salt-sensitive rats. W, week. Heart tissue extracts in Dahl salt-sensitive rats were prepared from rats fed the high-salt diet (H) and the low-salt diet (L) as a control at the cardiac hypertrophy stage (11W) and the heart failure stage (16W), and subjected to SDS-PAGE (20 µg of protein) and immunoblotting with the indicated isoform-specific antibodies, as described in the Methods. (A) The figure shows representative immunoblots. (B) The intensity of each band on the immunoblot was quantified by densitometric scanning. The results for the high-salt diet (H) are relative to PKC expression in hearts from the low-salt diet (L) when samples from the high-salt fed rats (H) and low-salt fed rats (L) were run in parallel. Results for the low-salt diet (L) are normalized to 1 and the SEM for this group represents the variation observed between individual hearts (means for at least six rats); p 0.01 and p 0.05 vs. control.
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The PKC isoforms could thus be divided into two groups based on their patterns of expression at the cardiac hypertrophy and heart failure stages.
Discussion
Although the signaling pathways in cardiac hypertrophy and congestive heart failure have been frequently investigated, they remain poorly defined. Accumulating evidence suggests that the patterns of PKC isoform expression may change during the process from cardiac hypertrophy to congestive heart failure (30) (31) (32) (33) (34) . Identification of the differential regulatory mechanism of PKC isoforms might provide new therapeutic targets for PKC isoform-selective inhibitors and activators.
In the present work, we did not evaluate their individual activities because it is highly difficult to do so with precision in vivo. This was a limitation of the present study. Nonetheless, the patterns of PKC isoform expression might provide further insight into the signal transduction pathways. The differential changes in the expression of PKC isoforms have been reported in experiments using in vivo models that cause cardiac remodeling. In the cardiac hypertrophic response, PKCβ and ε were found to increase and PKCα, δ, and ζ to remain unchanged when rats were subjected to pressure-overloaded cardiac hypertrophy by loose banding of the ascending aorta (35) . There was a substantial increase in PKCδ with the activation of the cardiac renin-angiotensin system in rats with experimental hyperthyroidism, while there was no significant change in PKCα, γ, and λ, and decreased PKCε under these conditions (36) . PKCε increased significantly in spontaneously hypertensive rats (SHR), which exhibit genetic hypertension similar to that of Dahl salt-sensitive rats (37) . In congestive heart failure, PKCα, β, γ, and ε decreased and PKCζ was not significantly modified when rabbits underwent heart failure induced by a double hemodynamic overload (aortic insufficiency followed by an aortic stenosis) (38) . PKCα and β increased and PKCε was not significantly changed in the failing human heart due to dilated and ischemic cardiomyopathy (15) .
Several functions of individual PKC isoforms have recently become clear through in vitro experiments and analysis of transgenic mice. Transgenic mice with an increased number of L-type calcium channels and PKCα activation developed cardiac hypertrophy and severe cardiac dysfunction (39) . Transgenic mice overexpressing PKCβ2 exhibited cardiac hypertrophy and decreased left ventricular performance; this depressed cardiac function improved after the superfusion of a PKCβ-selective inhibitor (40) (41) (42) . Both transgenic mice that overexpressed active PKCε and those that overexpressed the peptide that enhances PKCε translocation demonstrated cardiac hypertrophy with normal in vivo cardiac function (16, (43) (44) (45) . These reports suggest that PKCα and β are involved in the development of cardiac hypertrophy and heart failure, and that PKCε plays a role in the physiological hypertrophic responses and cardioprotective actions.
Since we compared the expression profile of PKC isoforms at the stages of cardiac hypertrophy and heart failure consecutively in the same model, our results would seem to be interesting in terms of elucidating the molecular mechanism of cardiac remodeling. In a recent investigation similar to that reported here, Inagaki et al. fed Dahl salt-sensitive rats a high-and low-salt diet (46) . Their results indicated that PKCε showed a 94% increase at the cardiac hypertrophy stage (11 weeks of age (W)) and returned to the control level at the heart failure stage (17W), whereas PKCβ increased by about 150% at the heart failure stage. These findings are consistent with ours and suggest differential effects between PKCβ and PKCε during the course from cardiac hypertrophy stage to heart failure stage.
However, because of the isoform-specificity, there is controversy concerning several cardiac functions of PKC. For example, several studies have reported that PKCβ is not important for the development of cardiac hypertrophy (47) , and transgenic mice with enhanced PKCε function have shown an increase in the level of a marker of morbid cardiac hypertrophy (16, (43) (44) (45) . Furthermore, there is a report that shows that PKCδ worsens cardiac ischemic injury, while another report paradoxically shows that PKCδ is involved in preconditioning and improves damage caused by cardiac ischemia (16, 48, 49) . These results strongly suggest the danger of applying PKC isoform-specific inhibitors or activators as a therapeutic strategy before PKC isoform-specific functions are clearly elucidated in the process of cardiac remodeling.
We find that there are two distinct groups of PKC isoforms with respect to the pattern of PKC expression in cardiac hypertrophy and heart failure. Our data indicate that PKCα, β, and δ are up-regulated from the stage of cardiac hypertrophy extending to congestive heart failure, but PKCε and aPKCs are up-regulated especially in cardiac hypertrophy and that the degree of this up-regulation tends to decline in congestive heart failure. These results suggest that all PKC isoforms (PKCα, β, δ, ε, and aPKCs) expressed in the heart may have similar functions at the cardiac hypertrophy stage, but two groups of PKC isoforms (PKCα, β, δ, and PKCε, aPKCs) have different functions at the congestive heart failure stage.
